Events News Press release

SeqOne Genomics announces Portuguese distribution partnership

20 October 2022

SeqOne has appointed ILC Instrumentos de Laboratório to distribute its genomic analysis software platform in Portugal, and to accelerate the availability of its advanced genomic analysis solutions.

Montpellier, France – Lisboa, Portugal – September 30th 2022 – SeqOne Genomics, provider of next-generation genomic analysis solutions for personalized medicine is proud to announce a new strategic partnership with  ILC Instrumentos de Laboratório Científicos to facilitate access to its genomic analysis solutions in Portugal.  Through this partnership, ILC Instrumentos de Laboratório Científicos has been appointed as a value added distributor in Portugal.

Nicolas Philippe, CEO co-founder of SeqOne Genomics, said “We were impressed with the capabilities of ILC to provide the high levels of qualified support and customer service that we feel are essential to medical teams performing genomic analysis in clinical environments. Having a strong local partner in Portugal is key in our European expansion to make genomic testing available to all who need it.

The new distribution partnership signals SeqOne’s intention to capitalize on the fast-growing personalized medicine market in Portugal. 

As the Portuguese market embraces personalized medicine, the market for genomic analysis solutions is expanding rapidly. SeqOne’s high performance genomic analysis platform gives us the confidence that we can address the needs of the market and thus capitalize on this growth. We were impressed by SeqOne’s ability to support the full range of genomic analysis requirements, from simple analyses of small gene panels to the entire genome in both cancer and inherited diseases.  This means that we can offer a complete solution that addresses our customers’ needs.” said Cristina Iglésias da Costa CEO of ILC.

About SeqOne Genomics

SeqOne Genomics offers high-performance genomic analysis solutions for healthcare providers treating patients suffering from cancer, rare and hereditary diseases as well as pharmaceutical companies developing new therapies. The solution leverages advanced machine learning coupled with the company’s proprietary genomics operating system to dramatically reduce turnaround times and costs while delivering comprehensive and actionable insights for personalized medicine. The company has won numerous awards including the iLab award and the ARC cancer foundation’s Hélène Stark prize. Investors include Elaia, IRDI Capital Investissement, Merieux Equity Partners, Omnes and Software Club. More information at: https://seqone.com

SeqOne Genomics media relations  

  • Annie-Florence Loyer – afloyer@newcap.fr / +33 (6) 88 20 35 59
  • Juliette Milleret – jmilleret@newcap.fr /+33 (6) 98 50 21 93

About ILC Instrumentos de Laboratório Científicos :

ILC has been in the Portuguese market since 1977 and has since been supporting the scientific community in the pursuit of knowledge and excellence. ILC has since partnered with some of the best companies in the world of Chemistry, Biology and Industry, in order to bring to Portugal the right technology and knowledge to allow its customers to reach their goals in the search of a better world.

Need help improving your genomic analysis process ?
We'd love to help !